Sec Form 5/A Filing - TRAVERSA SERGIO @ RELMADA THERAPEUTICS, INC. - 2022-12-31

FORM 5/A Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person TRAVERSA SERGIO 2. Issuer Name and Ticker or Trading Symbol RELMADA THERAPEUTICS, INC. [ RLMD] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X __ Director _____ 10% Owner X __ Officer (give title below) _____ Other (specify below) CEO (Last) (First) (Middle) C/O RELMADA THERAPEUTICS, INC., 2222 PONCE DE LEON BLVD, 3RD FLOOR 3. Date of Earliest Transaction (MM/DD/YY) 12/31/2022 (Street) CORAL GABLES, FL33134 4. If Amendment, Date Original Filed (MM/DD/YY) 02/02/2023 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Stock Option (right to buy) $ 16 07/08/2021 G( 1 ) V 4,131 ( 2 ) 07/10/2022 Common Stock 4,131 $ 0 0 D Stock Option (right to buy) $ 16 07/08/2021 G( 1 ) V 27,123 ( 3 ) 09/30/2023 Common Stock 27,123 $ 0 6,165 D Stock Option (right to buy) $ 54 07/08/2021 G( 1 ) V 8,231 ( 4 ) 02/23/2025 Common Stock 8,231 $ 0 3,019 D Stock Option (right to buy) $ 43.47 07/08/2021 G( 1 ) V 131,250 ( 5 ) 12/19/2029 Common Stock 131,250 $ 0 218,750 D Stock Option (right to buy) $ 33.43 07/08/2021 G( 1 ) V 31,250 ( 6 ) 01/07/2031 Common Stock 31,250 $ 0 225,000 D Stock Option (right to buy) $ 33.43 09/28/2022 G( 1 ) V 62,500 ( 6 ) 01/07/2031 Common Stock 62,500 $ 0 162,500 D Stock Option (right to buy) $ 33.43 09/28/2022 G( 1 ) V 87,500 ( 7 ) 01/07/2031 Common Stock 87,500 $ 0 162,500 D

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other TRAVERSA SERGIO C/O RELMADA THERAPEUTICS, INC. 2222 PONCE DE LEON BLVD, 3RD FLOOR CORAL GABLES, FL33134 X CEO Signatures /s/ Sergio Traversa 02/06/2023 Signature of Reporting Person Date

Explanation of Responses:

( 1 )Represents a bona fide gift of stock options to a family trust. An independent trustee is trustee of the trust. ( 2 )The options were granted on July 10, 2012. 25% of the options vested upon the grant date and the remaining 75% of the options vested in equal quarterly increments over the next four (4) years, so that the last set of options vested in July 2016. ( 3 )The options were granted on September 30, 2013. 25% of the options vested upon the date of grant and the remaining 75% of the options vested in equal quarterly increments over the next four (4) years, so that the last set of options vested in September 2017. ( 4 )The options were granted on February 15, 2015. 6.25% of the options vested each quarter from the date of grant. ( 5 )The options were granted on December 19, 2019. 6.25% of the options vest each quarter from the date of grant. ( 6 )The options were granted on January 7, 2021. 6.25% of the options vest each quarter from the date of grant. ( 7 )The options were granted on January 7, 2021. 25% of the options vested one year from the grant date, and thereafter in equal quarterly increments of 6.25% over the following three years.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.